CERTOLIZUMAB PEGOL IN PATIENTS WITH CROHN'S DISEASE: A LONG TERM UPDATE OF COMPASSIONATE USE

被引：1
|
作者：
Mocciaro, F. [1 ]
Renna, S. [1 ]
Orlando, A. [1 ]
Olivo, M. [1 ]
Sinagra, E. [1 ]
Cottone, M. [1 ]
机构：
[1] Villa Sofia V Cervello Hosp, Dept Med, Palermo, Italy
来源：
DIGESTIVE AND LIVER DISEASE | 2011年 / 43卷
关键词：
D O I：
10.1016/S1590-8658(11)60353-8
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S189 / S189
页数：1
相关论文
共 50 条
  • [31] Severe Crohn's disease symptoms are relieved by certolizumab pegol
    Feagan, Brian G.
    Coteur, Geoffroy
    Keininger, Doroth L.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 : S471 - S471
  • [32] Successful treatment of fistulizing Crohn's disease with certolizumab pegol
    Danese, Silvio
    Stefanelli, Tommaso
    Omodei, Paolo
    Zatelli, Stefania
    Bonifacio, Cristiana
    Balzarini, Luca
    Repici, Alessandro
    Malesci, Alberto
    INFLAMMATORY BOWEL DISEASES, 2008, 14 (02) : 292 - 293
  • [33] Use of Certolizumab Pegol in the Management of Acute Extraintestinal Manifestations of Active Crohn's Disease
    Randall, Charles
    Ford, Janet
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 : S354 - S354
  • [34] CERTOLIZUMAB PEGOL IN CROHN'S DISEASE REFRACTORY TO INFLIXIMAB AND ADALIMUMAB
    Jose, Morales Lara Ma
    Penella Monica, Martinez
    Guzman Diana, Lacruz
    Vidal Vanessa, Jorge
    Maneiro Vicente, Santaclara
    Sanchez Senador, Moran
    del Carmen, Mira Sirvent Ma
    ATENCION FARMACEUTICA, 2009, 11 (03): : 178 - 180
  • [35] Serum Certolizumab Pegol Levels and Antibodies to Certolizumab Pegol Are Associated With C-Reactive Protein Levels in Patients With Crohn's Disease
    Yarur, Andres
    Hauenstein, Scott
    Czul, Frank
    Lockton, Steven
    Quintero, Maria
    Barkin, Jamie
    Jain, Anjali
    Singh, Sharat
    Abreu, Maria
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S523 - S523
  • [36] Efficacy of Certolizumab Pegol in an Unselected Crohn's Disease Population: Long-Term Data of the FACTS III Survey
    Vavricka, Stephan R.
    Rogler, Gerhard
    Schoepfer, Alain
    Seibold, Frank
    Borovicka, Jan
    Frei, Pascal
    Manser, Christine N.
    Scharl, Michael
    Misselwitz, Benjamin
    Straumann, Alex
    Michetti, Pierre F.
    Biedermann, Luc
    GASTROENTEROLOGY, 2015, 148 (04) : S868 - S868
  • [37] Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey
    Vavricka, Stephan R.
    Spasojevic, Milos
    Rogler, Gerhard
    Schoepfer, Alain M.
    Seibold, Frank
    Borovicka, Jan
    Frei, Pascal
    Zeitz, Jonas
    Greuter, Thomas
    Manser, Christine
    Scharl, Michael
    Misselwitz, Benjamin
    Straumann, Alex
    Michetti, Pierre
    Biedermann, Luc
    DIGESTIVE DISEASES, 2017, 35 (05) : 423 - 432
  • [38] Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease and Secondary Failure to Infliximab
    Sandborn, William J.
    Abreu, Maria T.
    D'Haens, Geert
    Colombel, Jean-Frederic
    Vermeire, Severine
    Mitchev, Krassimir
    Jamoul, Corinne
    Fedorak, Richard N.
    Spehlmann, Martina E.
    Wolf, Douglas C.
    Lee, Scott
    Rutgeerts, Paul
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2010, 8 (08) : 688 - 695
  • [39] Mucosal Healing in Patients Receiving Certolizumab Pegol for Crohn's Disease (CHARTER Study)
    Randall, Charles
    Herrera, Christian
    Taboada, Carlo
    Fincke, Christopher
    Havranek, Russell
    Zurita, Franz
    Stump, David
    Gossen, Gary
    Vidaurri, Daniela
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 : S436 - S437
  • [40] CIMZIA (Certolizumab Pegol) is effective in the treatment of Crohn's Disease patients with open fistulas
    Schreiber, S.
    Lawranc, I
    Thomsen, O.
    Hanauer, S.
    Bloomfield, R.
    Sandborn, W.
    INFLAMMATORY BOWEL DISEASES, 2008, 14 (12) : S1 - S1
12345